GeneYouIn Revenue and Competitors
Estimated Revenue & Valuation
- GeneYouIn's estimated annual revenue is currently $2M per year.
- GeneYouIn's estimated revenue per employee is $155,000
Employee Data
- GeneYouIn has 13 Employees.
- GeneYouIn grew their employee count by 0% last year.
GeneYouIn's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Scientific Officer | Reveal Email/Phone |
3 | Chief Technology Officer | Reveal Email/Phone |
GeneYouIn Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.7M | 9 | -72% | $39.4M | N/A |
#2 | $0.9M | 11 | -83% | $23.8M | N/A |
#3 | $87.6M | 565 | 6% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $7.8M | 50 | -68% | N/A | N/A |
#6 | $13.5M | 87 | 30% | N/A | N/A |
#7 | $17.8M | 115 | -6% | N/A | N/A |
#8 | $0.9M | 11 | -39% | N/A | N/A |
#9 | $13.6M | 88 | -20% | $86M | N/A |
#10 | $20M | 129 | -12% | N/A | N/A |
What Is GeneYouIn?
GeneYouIn brings precision medicine to public and private health plans globally. It is commercializing Pillcheckâ„¢, a genomics-guided personalized medication management service that predicts how medications work, limiting potential side effects and helping individuals feel better, faster. Pillcheck's proprietary platform connects healthcare providers, and consumers while reducing exposure to unnecessary costs for payers. Pillcheck works with insurers, corporate benefit plans, and benefit advisors to bring precision medicine to the workplace, following best practices around genetic non-discrimination legislation and health data privacy laws.
keywords:N/AN/A
Total Funding
13
Number of Employees
$2M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.4M | 13 | -7% | $3M |
#2 | $1.1M | 13 | N/A | N/A |
#3 | $0.9M | 13 | N/A | N/A |
#4 | $2M | 13 | 0% | N/A |
#5 | $1.9M | 13 | -7% | N/A |